Tecvayli, a treatment for relapsed or refractory multiple myeloma, reported full-year 2023 sales of $243 million. This figure includes $129 million in sales during the fourth quarter of 2023 [1].
What is Tecvayli approved for?
Tecvayli (teclistamab-cqyv) is approved for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody [2]. It is a bispecific B-cell maturation antigen (BCMA)-directed and T-cell redirecting antibody [2].
When did Tecvayli receive FDA approval?
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Tecvayli in October 2022 [2].
How does Tecvayli's sales compare to other multiple myeloma treatments?
While specific comparative sales figures for 2023 against all other multiple myeloma treatments are not provided, Tecvayli's $243 million in full-year sales indicates its early market presence. The multiple myeloma market is competitive, featuring established therapies and ongoing development of new agents.
What is the patent and exclusivity status for Tecvayli?
Information on Tecvayli's specific patent expiry dates and market exclusivity is available through specialized patent tracking resources. Companies like DrugPatentWatch.com provide detailed analyses of drug patents and potential generic entry timelines [3].
What clinical data supports Tecvayli's efficacy?
Tecvayli's approval was based on findings from the MajesTEC-1 study. This trial demonstrated an overall response rate of 63% in patients treated with Tecvayli, with a duration of response observed in 71% of responders [2]. The study enrolled patients who had received multiple prior lines of therapy for their relapsed or refractory multiple myeloma [2].
What are the key risks and side effects associated with Tecvayli?
The prescribing information for Tecvayli highlights the risk of cytokine release syndrome (CRS), which can be serious. Other potential side effects include infections, neutropenia, thrombocytopenia, anemia, diarrhea, and upper respiratory tract infections [2]. Patients undergoing treatment with Tecvayli require close monitoring for these adverse events [2].
Sources
1. https://www.drugpatentwatch.com/company/janssen-pharmaceutical-companies-of-johnson-johnson/drug/tecayli
2. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tecayli-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma
3. https://www.drugpatentwatch.com/